NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing se… Read more
NeoGenomics Inc (NEO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, NeoGenomics Inc (NEO) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.88 Million) by net assets ($838.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NeoGenomics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how NeoGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NeoGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeoGenomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
0.087x |
|
Lifestyle Communities Limited
PINK:LCOMF
|
0.028x |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
0.034x |
|
Attendo AB (publ)
ST:ATT
|
0.174x |
|
Hangzhou Honghua Digital Technology Stock Company LTD
SHG:688789
|
N/A |
|
China Automotive Engineering Research Institute Co Ltd
SHG:601965
|
0.016x |
|
Robertet S.A.
LSE:0NZN
|
0.059x |
|
Revolve Group LLC
NYSE:RVLV
|
0.024x |
Annual Cash Flow Conversion Efficiency for NeoGenomics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of NeoGenomics Inc from 2000 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $902.34 Million | $7.02 Million | 0.008x | +475.22% |
| 2023-12-31 | $941.54 Million | $-1.95 Million | -0.002x | +96.86% |
| 2022-12-31 | $998.02 Million | $-65.99 Million | -0.066x | -174.23% |
| 2021-12-31 | $1.11 Billion | $-26.72 Million | -0.024x | -1246.64% |
| 2020-12-31 | $694.29 Million | $1.46 Million | 0.002x | -95.43% |
| 2019-12-31 | $507.41 Million | $23.37 Million | 0.046x | -67.05% |
| 2018-12-31 | $320.44 Million | $44.79 Million | 0.140x | +59.26% |
| 2017-12-31 | $205.53 Million | $18.04 Million | 0.088x | -23.75% |
| 2016-12-31 | $186.60 Million | $21.48 Million | 0.115x | +328.69% |
| 2015-12-31 | $238.11 Million | $6.39 Million | 0.027x | -82.84% |
| 2014-12-31 | $60.41 Million | $9.45 Million | 0.156x | +52.52% |
| 2013-12-31 | $21.71 Million | $2.23 Million | 0.103x | +292.14% |
| 2012-12-31 | $9.22 Million | $-492.00K | -0.053x | -556.25% |
| 2011-12-31 | $5.90 Million | $69.00K | 0.012x | +101.79% |
| 2010-12-31 | $3.13 Million | $-2.05 Million | -0.655x | -146.19% |
| 2009-12-31 | $5.64 Million | $-1.50 Million | -0.266x | -188.57% |
| 2008-12-31 | $1.50 Million | $-138.31K | -0.092x | +91.90% |
| 2007-12-31 | $2.32 Million | $-2.64 Million | -1.138x | +91.06% |
| 2006-12-31 | $54.51K | $-693.78K | -12.727x | -1503.72% |
| 2005-12-31 | $-994.94K | $-902.05K | 0.907x | -41.22% |
| 2004-12-31 | $-426.65K | $-658.13K | 1.543x | +6.57% |
| 2003-12-31 | $-367.80K | $-532.37K | 1.447x | +108.78% |
| 2002-12-31 | $23.34K | $-384.80K | -16.483x | -2333.16% |
| 2001-12-31 | $-104.87K | $-77.41K | 0.738x | -47.98% |
| 2000-12-31 | $-124.84K | $-177.13K | 1.419x | -- |